Thursday, December 01, 2016 9:13:00 AM
When I'm looking at these "undiscovered" little companies. I'm more interested in what they have, rather than what they do. In terms of the what they have, I'm usually looking for patents or some sort of proprietary information. The next thing I'm looking for is validation of what they have. In the case of Zivo the Zoetis relationship is validation to me. Whether or not a a deal ever materializes, there was enough to ZIVO that Zoetis wanted to take a deeper look. Of course, Zoetis knows more about this industry than I do. The continued involvement of HEPI is also validation. Firms like that have the ability to much more in depth due diligence than I can possibly do.
My .30+, is more based on trading history and market cap, rather than on a fundamental valuation. As you know it is difficult to value a pre revenue company, because the only valuation metrics available are theoretical. In the case of ZIVO, they currently have a market cap of around 15 million, if you take into account the fact that the convertible notes will convert at some time that would bring the market cap up to around 25 million(very rough numbers) Given the fact that the market verticals zivo is in, I believe these valuations are still modest. If they are able to get a agreement in place with a partner of size, I believe at that point the market will begin to look at the company in terms of "buy out" value as opposed to an earnings based valuation. With the stock at .30 cents, that still represents a reasonable valuation to me, assuming a deal is in place. At .50 the valuation begins to get a little steep, at that point we'd have mkt cap of over $65 million and a post note conversion valuation of roughly $100 million. So, in my view, it would take a pretty special deal or multiple deals to justify a valuation at those levels.
Also, I look at the historical trading of the stock. I am not a chartist but I do believe looking at past trading does have some merit. With that said, I think we could see the stock go to the .20's in the short term as long as we get a little news. The move from .20 to .30, I think will be take a bit longer, it looks like there's a fair amount of supply to chew through between .20 and .30.
Recent ZIVO News
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/26/2024 05:36:56 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/26/2024 12:05:12 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 04/09/2024 03:49:14 PM
- Form SCHEDULE 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 03/14/2024 01:16:49 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/15/2024 09:45:37 PM
- Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities • Edgar (US Regulatory) • 02/15/2024 01:54:37 PM
- ZIVO Bioscience Reports Additional Findings from Positive 42-Day Coccidiosis Challenge Study • Business Wire • 02/07/2024 09:54:00 PM
- ZIVO Bioscience Announces Uplisting to OTCQB Market • Business Wire • 01/29/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/17/2024 09:11:48 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/05/2024 10:17:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 09:05:16 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/03/2024 10:23:55 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/02/2024 09:12:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/27/2023 02:29:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/22/2023 09:21:58 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2023 09:18:41 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 10/30/2023 05:20:31 PM
- ZIVO Bioscience Initiates 42-Day Validation Study with Immune-Modulating Product for the Prevention and Treatment of Coccidiosis in Broiler Chickens • Business Wire • 10/30/2023 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/26/2023 12:56:59 PM
- ZIVO Bioscience Announces Reverse Stock Split • Business Wire • 10/26/2023 12:30:00 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 10/04/2023 09:08:51 PM
- ZIVO Bioscience to Present at the Dawson James Small Cap Growth Conference • GlobeNewswire Inc. • 10/03/2023 12:30:00 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM